Munich-based drug developer SuppreMol launches as new company with financing from Z-Cube
SuppreMol, a spin-off from the Max-Planck Institute of Biochemistry in Munich, Germany, has become a new company using finance from Z-Cube, the corporate venture capital arm of the Zambon Group.
SuppreMol, a spin-off from the Max-Planck Institute of Biochemistry in Munich, Germany, has become a new company using finance from Z-Cube, the corporate venture capital arm of the Zambon Group.
SuppreMol is working on the development of drugs for the treatment of autoimmune diseases and allergies through innovative therapeutic approaches centred on Fc-receptors. The development of these drugs is based on patent rights owned by the Max-Planck Society and licensed to SuppreMol by the Society's Technology Transfer office, Garching Innovation.
Ulrich Mahr, senior start-up manager of Garching Innovation, said: 'The combination of excellent research results from the Max-Planck Institute of Biochemistry with the strong pharmaceutical background of Z-Cube form a very fruitful basis for the future success of our new portfolio company SuppreMol'.
Founded by Dr Uwe Jacob, Dr Peter Sondermann and Professor Robert Huber (a Nobel Prize winner for protein chemistry), SuppreMol is the first European project to be launched as a new company under the auspices of Z-Cube.